Frequently asked.
Twelve questions a senior pharma or technology applicant tends to ask before deciding to apply. Twelve direct answers, on the record. If yours is not here, write to room@aiforpharma.ai.
- 01
What is AIforPharma?
AIforPharma is a recurring consortium that convenes senior decision-makers from India's pharmaceutical industry with the technology companies and AI engineers building for them. It is being convened in 2026 by the team behind PharmaOS. The intended cadence is three to four editions per year, alternating between Indian cities. Attendance is by application.
- 02
Has AIforPharma held an edition before?
No. The consortium is in its founding period and the first edition has not yet been held. Applications for the founding edition are open and reviewed weekly. The date and venue will be announced to invited applicants first.
- 03
Who organises AIforPharma?
The team behind PharmaOS, a Super AI product that lets pharma companies query their own data in plain language. The consortium grew out of conversations the PharmaOS team was already having with R&D heads, regulatory leaders, and CIOs across the Indian pharmaceutical industry. AIforPharma is editorially independent of PharmaOS; the product is one demonstration among many at any given edition.
- 04
Who attends AIforPharma editions?
From pharma: Chief Information Officers, Chief Digital Officers, Heads of R&D, Heads of Regulatory, Heads of Medical Affairs, Heads of Pharmacovigilance, Heads of Commercial, and Heads of Manufacturing and Quality at operating pharma companies in India. From technology: senior leaders at foundation-model companies, enterprise cloud platforms, data and observability vendors, and pharma-focused AI startups. Both sides go through the same application review and sit in the same room.
- 05
When is the first edition?
The date is being finalised and will be announced to invited applicants first. Applicants who are accepted for the founding edition will receive a formal invitation by email with the date, venue, and agenda, along with sufficient notice to plan around it.
- 06
Where will the first edition be held?
An Indian city, in person. The specific venue is being finalised and will be announced to invited applicants. Future editions are intended to alternate between Indian cities.
- 07
How is AIforPharma different from a pharma technology conference?
A conference is one-off, broadcast-shaped, measured by attendee count, and built around a main stage and sponsor booths. AIforPharma is recurring, conversation-shaped, measured by who is in the room and what they argue about, and built around four working sessions, two live demonstrations, and a curated dinner. There is no main stage, no sponsor hall, and no general ticket on sale.
- 08
Is there a cost to attend?
Pricing for accepted applicants is announced privately when the date and venue are confirmed. The intent is to keep the room senior and the conversation honest, not to monetise the event. There is no public ticket; all attendance is by application and invitation.
- 09
What gets discussed at an edition?
The intended structure is four working sessions across R&D, regulatory, commercial, and medical affairs, plus two live demonstrations of AI applied to real pharma problems. Sessions are opened by a pharma function leader naming a workflow they are trying to improve, paired with an engineer or AI leader who has built or is building for that workflow. Specific examples of the conversation we expect: how a Brand Manager attributes secondary-sales movement in a territory back to a specific MR-level intervention with and without the IQVIA layer; how a regulatory team treats AI-drafted ANDA responses in the audit trail; where SMSRC Rx and IQVIA secondary diverge, and what that disagreement is telling you. Demonstrations are real systems against real data, not slideware. Failures are discussed as candidly as successes.
- 10
What happens between editions?
Between editions, the consortium will live in a private group of attendees. The intent is for the group to function as the always-on extension of the in-person conversation: a question on retrieval-augmented generation over a regulatory document set gets answered by the person who built that pipeline at a peer company. The next edition's agenda is shaped by what the group has been arguing about. Membership in the group is extended to attendees after their first edition; the group is moderated, off the record, and small. The group does not exist yet; it begins with the founding edition.
- 11
How does AIforPharma decide who to invite?
Applications are reviewed in full by the organising team. We are reading for substance: a specific problem the applicant is willing to discuss openly, a counter-view to the consensus, or experience the room can learn from. We invite by role and contribution, not by logo. All applicants receive a reply, accepted or not.
- 12
I am not at director level yet. Can I still be involved?
The application is reserved for senior decision-makers because the format depends on the room being small and high-trust. If you are a working practitioner (an R&D scientist, a regulatory manager, an AI engineer at a CDMO), write to room@aiforpharma.ai and we will route the request appropriately. Several adjacent formats are being considered for practitioners; we will publish them as they exist.
Your question is not on this list?